UK Breast Cancer Therapeutics Market Analysis Report 2022 to 2030

UK Breast Cancer Therapeutics Market Analysis

$ 3999

The UK breast cancer therapeutics market is at around $473 Mn in 2022 and is expected to witness a growth of $1,083 Mn with a CAGR of 10.9% for the year 2022-2030. The major market drivers include the rising prevalence of breast cancer and its awareness programs in the UK. The market is segmented by therapy, by cancer type, and by distribution channel. Pfizer, AstraZeneca, and Bayer are some of the leading brands in the UK breast cancer therapeutics market.

ID: IN10GBPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: UK AUTHOR: Parul Choudhary

Buy Now

UK Breast Cancer Therapeutics Market Executive Analysis

The UK Breast Cancer Therapeutics market size is at around $473 Mn in 2022 and is projected to reach $1,083 Mn in 2030, exhibiting a CAGR of 10.9% during the forecast period. England's Department of Health and Social Care is responsible for funding health services. In England, the Department of Health and Social Care anticipates spending $195 Bn in 2022–2023 on these programs. The Department of Health and Human Services transfers the majority of its money ($152.6 Bn in 2022–2023) to National Health Service (NHS) England and NHS Improvement to be used for funding health services.

With one woman being diagnosed with breast cancer every 10 minutes, it is the most frequent cancer among women in the UK. In the UK, there are about 35,000 persons who have secondary breast cancer. By the time breast cancer is detected, it has spread to about 5% of women. Breast cancer survival rates are rising and have doubled in the UK over the past 40 years as a result of advancements in diagnosis, treatment, and care as well as earlier detection through screening and a target-driven approach that includes early treatment.

UK breast cancer therapeutics market analysis

Market Dynamics

Market Growth Drivers

The main drivers of the market's expansion are the rising prevalence of breast cancer and the growing awareness of breast cancer diagnosis and treatment. For women aged 70 and older, Public Health England (PHE) launched the "Be Clear on Cancer" campaign in 2015 to raise awareness of the risk of breast cancer.

Market Restraints

The main obstacle to the UK breast cancer market is the patent expiration of several successful medications. The expansion of the UK market for breast cancer treatments is also hampered by strict laws and regulations, as well as the adverse outcomes of chemotherapy.

Competitive Landscape

Key Players

GlaxoSmithKline (UK)
Johnson & Johnson (UK)
Pfizer (UK)
AstraZeneca (UK)
Bayer (UK)
Mylan NV
Merck & Co., Inc.
Novartis International AG
F. Hoffmann-La Roche AG
Sanofi S.A.

Healthcare Policies and Regulatory Landscape.

Treatment for breast cancer is covered by the National Health Service (NHS) in the UK. This covers medical procedures including surgery, radiotherapy, and chemotherapy. Depending on the type and stage of cancer, and the patient's general health, multiple treatment options may be available. For people with breast cancer, the NHS also offers support services like counseling and access to support groups.

Reimbursement Scenario

The National Institute for Health and Care Excellence (NICE) guidelines, which attempt to give NHS providers a structure on how to deliver the best and most cost-effective care to patients, are typically used to implement the reimbursement policy for breast cancer treatment. It offers periodically reviewed and updated guidelines for the detection, therapy, and management of diseases including breast cancer.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.